about
Antibody blockade of the Cripto CFC domain suppresses tumor cell growth in vivoActivins and activin antagonists in hepatocellular carcinomaRecent developments in β-cell differentiation of pluripotent stem cells induced by small and large moleculesIdentification of proteins involved in neural progenitor cell targeting of gliomas.Differential expression of follistatin and FLRG in human breast proliferative disordersConditional activin receptor type 1B (Acvr1b) knockout mice reveal hair loss abnormality.Effects of de-escalated bisphosphonate therapy on bone turnover biomarkers in breast cancer patients with bone metastases.Evidence of inhibin/activin subunit betaC and betaE synthesis in normal human endometrial tissue.Loss of function of e-cadherin in embryonic stem cells and the relevance to models of tumorigenesisExtratesticular interstitial and Sertoli cell tumors in previously neutered dogs and cats: a report of 17 casesThe Local Control of the Pituitary by Activin Signaling and Modulation.Activin enhances skin tumourigenesis and malignant progression by inducing a pro-tumourigenic immune cell response.Cell-type specific modulation of pituitary cells by activin, inhibin and follistatin.Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer.Suppression of activin A signals inhibits growth of malignant pleural mesothelioma cells.The role of activins during decidualisation of human endometrium.Activin B induces human endometrial cancer cell adhesion, migration and invasion by up-regulating integrin β3 via SMAD2/3 signalingActivin receptor signaling regulates prostatic epithelial cell adhesion and viability.Peroxisome proliferator-activated receptor gamma down-regulates follistatin in intestinal epithelial cells through SP1Activin A suppresses osteoblast mineralization capacity by altering extracellular matrix (ECM) composition and impairing matrix vesicle (MV) production.Elevated level of inhibin-alpha subunit is pro-tumourigenic and pro-metastatic and associated with extracapsular spread in advanced prostate cancerA phase II, multicentre trial evaluating the efficacy of de-escalated bisphosphonate therapy in metastatic breast cancer patients at low-risk of skeletal-related events.Antagonism of activin by activin chimeras.The role of activin in mammary gland development and oncogenesis.Follistatin as potential therapeutic target in prostate cancer.Activins and Inhibins: Roles in Development, Physiology, and Disease.SMAD3 Activation: A Converging Point of Dysregulated TGF-Beta Superfamily Signaling and Genetic Aberrations in Granulosa Cell Tumor Development?Inhibin-betaA and -betaB subunits in normal and malignant glandular epithelium of uterine cervix and HeLa cervical cancer cell line.Activin A/bone morphogenetic protein (BMP) chimeras exhibit BMP-like activity and antagonize activin and myostatin.An activin-A/C chimera exhibits activin and myostatin antagonistic properties.Serum follistatin in patients with prostate cancer metastatic to the bone.Increased serum activin-A differentiates alcoholic from cirrhosis of other aetiologies.Involvement of activin signaling in abnormalities of mouse vagina exposed neonatally to diethylstilbestrol.Activin regulates estrogen receptor gene expression in the mouse ovary.Reversal of a Blunted Follicle-Stimulating Hormone by Chemotherapy in an Inhibin B-Secreting Adrenocortical Carcinoma.Inhibin-βA subunit immunolabeling as a prognostic factor in endometrioid adenocarcinomas: a matter of evaluation?Expression of activin and inhibin subunits, receptors and binding proteins in human adrenocortical neoplasms.Increased activin A levels in prediabetes and association with carotid intima-media thickness: a cross-sectional analysis from I-Lan Longitudinal Aging Study.Inhibin B suppresses anoikis resistance and migration through the transforming growth factor-β signaling pathway in nasopharyngeal carcinoma
P2860
Q24316195-77B3EAF0-DD6E-47CA-A6CE-BB3745D3469DQ24646221-F8C856B1-D5D6-43E8-9F0D-96176A05DE0CQ26825664-8AF41FBE-852C-4852-BE70-D2CDC84AD31FQ33475160-A73D1437-25C1-4FE0-B48F-C69EDC8AF017Q33501385-40F78CCD-ED6E-4EE5-AF0F-644D311BC27CQ33726516-216F1F0B-3689-475E-8F77-83A720D7BE2CQ34325491-0382C7E1-5706-4ABC-BFAF-8446CC4EEE82Q34408341-E034E48D-D557-4BA6-A534-38A6250CF5E3Q34423998-8A93BE6E-3B66-4025-B1A2-AC22783C771FQ34881727-9ED755BC-9AB9-4BA4-990C-04D0EB30C5ACQ35214837-49D3968D-D0EC-46B3-AF64-AC7B69DFFA9AQ35639228-C6320DF8-A96A-4D65-93C9-38C355B3623DQ36007410-ADC24FE0-BA1D-4D28-8CF0-CC82447DF89CQ36354855-A6BE272F-8A39-4391-A891-DA19ECA0AC3EQ36451785-B08642A6-DB24-47F5-B596-47FA50C7354FQ36480573-CB412FCF-AAD4-44BE-891D-155419C3D0C0Q36544657-2D14989A-E6B3-4203-B533-19BBC3B783D0Q37133929-5D0F29E2-5ACE-4840-9FCB-98B4360F8C02Q37142538-E645FF71-EE38-42E2-B639-F61059D6FE38Q37214690-5F65B2C2-E4CF-480F-9B5E-8F2D538EBA27Q37225724-700DFE5D-2032-4F05-9126-B83626EC1581Q37656386-CE1CA40B-8951-44C5-8918-ED674002AC78Q37847427-F7A95F1C-25D0-4D6E-8EC4-D15AAD0066FDQ37863042-93A9F79B-9C08-4A0A-8C44-C28DC99F882FQ38086102-2E5AEE0B-DF88-4702-83C2-5C2F707B3E67Q38872337-AB681A2E-3B9A-4E77-97CE-E3A61D77AD3DQ38967398-1D7F3CF6-2F29-4E0D-954C-2910B0C58008Q39630960-7E6A6A50-29FD-4B7C-A7BB-01AC0C1C082CQ40041084-F3A02BEA-2D8C-4592-9A31-423784D1BA12Q40380199-5A72CEA7-7E05-4C2D-B410-B5F41B323655Q42972965-429B3B51-2AEB-40C8-8F7F-369982E7525FQ45330911-A269876A-95D7-495C-B5DF-E17195A04A92Q45400209-E410E204-972D-40C6-9869-7BC10D100F3CQ46939290-637D8C6E-DD6B-482D-8184-F635E1CF34D7Q52741514-4BE27AD2-5E63-40A5-8A32-8E7CC0388C6BQ53295028-B3DF9C6C-62AD-4D16-A454-D0FD6175BCE4Q54570296-7F7CFB2F-E666-408A-A8E5-22445701D050Q55457462-29A643D6-8690-4AD9-B9BF-69E802F4E515Q58719354-09B6F219-C73B-4698-B1B3-CA2223DA8D4B
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Activins and inhibins in endocrine and other tumors.
@ast
Activins and inhibins in endocrine and other tumors.
@en
Activins and inhibins in endocrine and other tumors.
@nl
type
label
Activins and inhibins in endocrine and other tumors.
@ast
Activins and inhibins in endocrine and other tumors.
@en
Activins and inhibins in endocrine and other tumors.
@nl
prefLabel
Activins and inhibins in endocrine and other tumors.
@ast
Activins and inhibins in endocrine and other tumors.
@en
Activins and inhibins in endocrine and other tumors.
@nl
P2093
P356
P1433
P1476
Activins and inhibins in endocrine and other tumors.
@en
P2093
Risbridger GP
Robertson DM
Schmitt JF
P304
P356
10.1210/ER.22.6.836
P577
2001-12-01T00:00:00Z